
Core Insights - Clene Inc. presented long-term results for CNM-Au8 treatment, showing improved survival and reduced neurofilament light (NfL) levels in ALS patients [1][2][5] Group 1: Survival Analysis - Survival analyses indicated a 60% decreased risk of death in patients treated with CNM-Au8 30 mg compared to matched PRO-ACT controls over a follow-up period of up to 3.5 years, with a hazard ratio of 0.431 (p=0.0002) [3][5] - The study included participants originally randomized to CNM-Au8 treatment and those who transitioned from placebo, totaling 70 patients [2][3] Group 2: Neurofilament Light Levels - In the NfL responder subset, participants showed an average NfL reduction of 28%, indicating decreased axonal loss, with a geometric mean ratio of 0.72 at Week 76 (p<0.0001) [4][5] - The NfL results were based on plasma samples from 99 participants treated with CNM-Au8 30 mg, demonstrating a continued significant decline in NfL levels compared to placebo [4] Group 3: Safety and Tolerability - CNM-Au8 was reported to be safe and well-tolerated during the open-label extension of the trial, with over 650 patient years of treatment exposure without any identified safety signals [1][5]